Evaluation of self-sampling-based cervical cancer screening strategy using HPV Selfy CE-IVD test coupled with home-collection kit: a clinical study in Italy.

COVID-19 HPV HPV Selfy Human papillomavirus Self-sampling VALHUDES

Journal

European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857

Informations de publication

Date de publication:
11 Dec 2023
Historique:
received: 05 09 2022
accepted: 03 08 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 10 12 2023
Statut: epublish

Résumé

Primary human papillomaviruses (HPV) cervical cancer screening can be strengthened by offering home-collection of biological specimen as a valuable option to increase screening coverage. As recommended by World Health Organization (WHO), screening programs should consider whether the inclusion of HPV self-sampling as a complementary option within their existing screening algorithms could address the gaps in current coverage. However, few HPV screening tests are validated for self-sampling according to international guidelines. This study aimed to test a self-sampling-based screening strategy, complementary to the main screening program based on clinician-collected cervical samples. The study took place in Trieste, Italy, and it aimed to evaluate the feasibility of self-testing at home under an opt-in system during COVID-19 pandemic in order to exploit self-sampling to reduce the screening delay generated by the lockdown. 500 women, who should have received the screening call in 2020, were asked, via phone call, to participate in the study. To whom agreed, a home-collection kit, including a vaginal dry swab for specimen collection, was sent. The recipients performed the sample self-collection and sent back the swab through traditional mail using a prepaid envelope. Once received by the hospital, the samples were analyzed with HPV Selfy (Ulisse BioMed, Italy), a CE-IVD HPV screening test specifically validated for self-collection. Results were further compared using cobas 80% women sent back their swab, showing one of the highest return rate obtained in comparable studies. 34 HPV-positive women were followed up and underwent the Pap test, that revealed 8 low squamous intraepithelial lesions (LSIL) cases, later triaged to colposcopy. HPV Selfy was confirmed to be an adequate test for self-sampling-based screening. This study further confirmed the feasibility of self-test at home screening strategy based on self-sampling with an opt-in system as a support method to enhance cervical cancer screening coverage in Italy. Enrolled women showed a high appreciation for this approach. HPV Selfy test demonstrated to be a valuable assay for cervical cancer screening based on home self-collection. ASUGI Trieste n. 16008/2018 and amendment 02-11/09/2020.

Sections du résumé

BACKGROUND BACKGROUND
Primary human papillomaviruses (HPV) cervical cancer screening can be strengthened by offering home-collection of biological specimen as a valuable option to increase screening coverage. As recommended by World Health Organization (WHO), screening programs should consider whether the inclusion of HPV self-sampling as a complementary option within their existing screening algorithms could address the gaps in current coverage. However, few HPV screening tests are validated for self-sampling according to international guidelines. This study aimed to test a self-sampling-based screening strategy, complementary to the main screening program based on clinician-collected cervical samples. The study took place in Trieste, Italy, and it aimed to evaluate the feasibility of self-testing at home under an opt-in system during COVID-19 pandemic in order to exploit self-sampling to reduce the screening delay generated by the lockdown.
METHODS METHODS
500 women, who should have received the screening call in 2020, were asked, via phone call, to participate in the study. To whom agreed, a home-collection kit, including a vaginal dry swab for specimen collection, was sent. The recipients performed the sample self-collection and sent back the swab through traditional mail using a prepaid envelope. Once received by the hospital, the samples were analyzed with HPV Selfy (Ulisse BioMed, Italy), a CE-IVD HPV screening test specifically validated for self-collection. Results were further compared using cobas
RESULTS RESULTS
80% women sent back their swab, showing one of the highest return rate obtained in comparable studies. 34 HPV-positive women were followed up and underwent the Pap test, that revealed 8 low squamous intraepithelial lesions (LSIL) cases, later triaged to colposcopy. HPV Selfy was confirmed to be an adequate test for self-sampling-based screening.
CONCLUSIONS CONCLUSIONS
This study further confirmed the feasibility of self-test at home screening strategy based on self-sampling with an opt-in system as a support method to enhance cervical cancer screening coverage in Italy. Enrolled women showed a high appreciation for this approach. HPV Selfy test demonstrated to be a valuable assay for cervical cancer screening based on home self-collection.
TRIAL REGISTRATION BACKGROUND
ASUGI Trieste n. 16008/2018 and amendment 02-11/09/2020.

Identifiants

pubmed: 38072937
doi: 10.1186/s40001-023-01263-8
pii: 10.1186/s40001-023-01263-8
pmc: PMC10712215
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

582

Informations de copyright

© 2023. The Author(s).

Références

Lancet Reg Health Eur. 2021 Nov 09;11:100235
pubmed: 34918001
Br J Cancer. 2014 Nov 25;111(11):2187-96
pubmed: 25247320
Int J Womens Health. 2015 Feb 02;7:149-54
pubmed: 25674016
Br J Cancer. 2011 Mar 15;104(6):915-20
pubmed: 21343937
Transpl Infect Dis. 2023 Apr;25(2):e14019
pubmed: 36695181
Med Princ Pract. 2008;17(5):351-64
pubmed: 18685274
Prev Med. 2020 Mar;132:105953
pubmed: 31911163
JAMA. 2002 Apr 24;287(16):2114-9
pubmed: 11966386
Int J Cancer. 2013 May 15;132(10):2223-36
pubmed: 22907569
Int J Womens Health. 2018 May 15;10:229-236
pubmed: 29805267
Br J Cancer. 2015 Feb 17;112(4):667-75
pubmed: 25633037
Eur J Cancer. 2015 Nov;51(16):2375-85
pubmed: 26296294
J Med Virol. 2017 Jun;89(6):1121-1124
pubmed: 27935070
Sex Transm Infect. 2017 Feb;93(1):56-61
pubmed: 28100761
Int J Environ Res Public Health. 2021 Dec 22;19(1):
pubmed: 35010314
Gynecol Oncol. 2023 Jan;168:39-47
pubmed: 36371904
Arch Public Health. 2021 Aug 30;79(1):155
pubmed: 34462004
Obstet Gynecol. 2013 Jun;121(6):1209-1216
pubmed: 23812454
Infect Agent Cancer. 2020 Feb 13;15:10
pubmed: 32082413
Radiol Oncol. 2018 Sep 14;52(4):399-412
pubmed: 30216191
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):109-113
pubmed: 33507893
Sex Transm Dis. 2018 Jan;45(1):42-48
pubmed: 28876298
Cancer Epidemiol Biomarkers Prev. 2021 Feb;30(2):245-247
pubmed: 33547144
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2016 Jul 15;139(2):281-90
pubmed: 26850941
J Prev Med Hyg. 2022 Oct 27;63(3):E415-E419
pubmed: 36415298
Infect Agent Cancer. 2020 Oct 14;15:61
pubmed: 33072179
J Transl Med. 2022 May 17;20(1):231
pubmed: 35581584
Int J Cancer. 2012 Mar 1;130(5):1128-35
pubmed: 21484793
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):661-668
pubmed: 33514604
J Low Genit Tract Dis. 2010 Oct;14(4):356-62
pubmed: 20885165
Tutor Quant Methods Psychol. 2012;8(1):23-34
pubmed: 22833776
Br J Cancer. 2011 Aug 23;105(5):694-7
pubmed: 21811250
Br J Cancer. 2023 Mar;128(5):805-813
pubmed: 36517552
Cancers (Basel). 2023 Mar 08;15(6):
pubmed: 36980555
Br J Cancer. 2009 Sep 1;101(5):871-4
pubmed: 19654577
Int J Cancer. 2015 Feb 1;136(3):646-55
pubmed: 24923998
Lancet. 2013 Sep 7;382(9895):889-99
pubmed: 23618600
Prev Med Rep. 2016 Dec 23;5:166-168
pubmed: 28050338
Int J Cancer. 2009 Feb 1;124(3):516-20
pubmed: 18973271
Curr Oncol. 2019 Jun;26(3):167-172
pubmed: 31285661
BMJ. 2010 Mar 11;340:c1040
pubmed: 20223872
Lancet Public Health. 2021 Jul;6(7):e522-e527
pubmed: 33939965
Eur J Cancer. 2012 Aug;48(12):1799-808
pubmed: 22172570
J Clin Virol. 2020 Jun;127:104375
pubmed: 32361328
Lancet Reg Health Eur. 2022 Feb 17;14:100332
pubmed: 35243475
BMC Cancer. 2018 Mar 9;18(1):273
pubmed: 29523108
Front Public Health. 2022 Dec 08;10:1003461
pubmed: 36568753
J Clin Virol. 2018 Oct;107:52-56
pubmed: 30195193
Int J Womens Health. 2021 Sep 18;13:841-859
pubmed: 34566436
Curr Oncol. 2018 Feb;25(1):13-18
pubmed: 29507479
Healthcare (Basel). 2022 Feb 28;10(3):
pubmed: 35326937
J Clin Microbiol. 2014 Mar;52(3):890-6
pubmed: 24391196
Int J Cancer. 2013 Jul;133(1):164-71
pubmed: 23233356
Int J Cancer. 2007 Apr 1;120(7):1505-10
pubmed: 17205514

Auteurs

Giulia Feltri (G)

UCO/SC Anatomia e Istologia Patologica, Azienda Sanitaria Universitaria Giuliano Isontina, Cattinara Hospital, Trieste, Italy.

Giulio Valenti (G)

Area Science Park, SS 14 - Km 163.5, Trieste, Italy.

Erica Isidoro (E)

UCO/SC Anatomia e Istologia Patologica, Azienda Sanitaria Universitaria Giuliano Isontina, Cattinara Hospital, Trieste, Italy.

Jaspreett Kaur (J)

Cervical Cancer Screening Coordination Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Marianna Treleani (M)

Cervical Cancer Screening Coordination Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Aurora Bartelloni (A)

Cervical Cancer Screening Coordination Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Claudia Mauro (C)

Cervical Cancer Screening Coordination Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Federica Spiga (F)

Cervical Cancer Screening Coordination Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Giulia Ticich (G)

UCO/SC Anatomia e Istologia Patologica, Azienda Sanitaria Universitaria Giuliano Isontina, Cattinara Hospital, Trieste, Italy.

Michela Di Napoli (M)

UCO/SC Anatomia e Istologia Patologica, Azienda Sanitaria Universitaria Giuliano Isontina, Cattinara Hospital, Trieste, Italy.

Claudia Biagi (C)

UCO/SC Anatomia e Istologia Patologica, Azienda Sanitaria Universitaria Giuliano Isontina, Cattinara Hospital, Trieste, Italy.

Maria Pachetti (M)

Area Science Park, SS 14 - Km 163.5, Trieste, Italy.

Sandro Centonze (S)

Clinical Research Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Santina Castriciano (S)

Copan Italia S.p.A., via F. Perotti 10, Brescia, Italy.

Sara Zanchiello (S)

Area Science Park, SS 14 - Km 163.5, Trieste, Italy.

Fabiola Giudici (F)

Service de Biostatistique et d'Épidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Équipe Labellisée Ligue Contre le Cancer, Oncostat, U1018, Inserm, Université Paris-Saclay, Villejuif, France.

Daniela Gerin (D)

Cervical Cancer Screening Coordination Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Fabrizio Zanconati (F)

UCO/SC Anatomia e Istologia Patologica, Azienda Sanitaria Universitaria Giuliano Isontina, Cattinara Hospital, Trieste, Italy. fabrizio.zanconati@asugi.sanita.fvg.it.
Department of Medical Science, University of Trieste, Trieste, Italy. fabrizio.zanconati@asugi.sanita.fvg.it.

Classifications MeSH